New MRI scan may predict pancreatic cancer treatment success

NCT ID NCT04700488

Terminated Diagnosis Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new type of MRI called 6D-MRI can predict how well pancreatic cancer patients respond to chemotherapy. Researchers will scan 36 patients before and during treatment to see if the MRI can spot signs of tumor activity and help guide surgery decisions. The study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 6D-MRI (a special type of MRI scan)
What this could lead to: If successful, this MRI technique could help doctors better predict how pancreatic cancer patients will respond to chemotherapy, guiding more personalized treatment.
What could go wrong: This is a small, early-stage study (36 participants) that is currently suspended. The MRI method is experimental and may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.